Aerie Pharmaceuticals reported $-19371000 in Net Income for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Aerie Pharmaceuticals AERI:US $ -19.37M 16.52M
Alimera Sciences ALIM:US $ -3.12M 2.84M
Amarin AMRN:US $ -69.96M 38.39M
Bluebird Bio BLUE:US $ -100.14M 22.01M
Cara Therapeutics CARA:US $ -4206000 23.54M
Endo International Ordinary Shares ENDP:US $ -1885.43M 1813.45M
Horizon Pharma HZNP:US $ 60.97M 143.29M
Insmed INSM:US $ -95645000 1.02M
JAZZ PHA JAZZ:US $ 34.66M 33.02M
Merk MRK:US $ 3944M 366M
Mirati Therapeutics MRTX:US $ -176.44M 11.94M
Novartis NOVN:VX SF 1694M 528M
Ophthotech OPHT:US $ -49.26M 14.73M
Pacira Pharmaceuticals PCRX:US $ 19.88M 13.05M
Regeneron Pharmaceuticals REGN:US $ 852.1M 121.4M
Revance Therapeutics RVNC:US $ -61.44M 2.91M
Supernus Pharmaceuticals SUPN:US $ 7.86M 17.75M
Teva Pharmaceutical Industries TEVA:US $ -233M 722M
Valeant Pharmaceuticals VRX:CN $ -186.64M 117.64M
Zoetis ZTS:US $ 529M 66M